The USFDA has approved the marketing of Eli Lilly and Company (NYSE: LLY)’s treatment for canine separation anxiety in conjunction with behaviour modification training: Reconcile™.
Reconcile™ (fluoxetine hydrochloride), the first selective serotonin reuptake inhibitor (SSRI) class of antidepressants approved by the FDA for treatment of canine separation and is the first Lilly product approved by the FDA for dogs and is now available to U.S. veterinarians.
Reconcile™ is a once-daily, chewable, flavored tablet that may be prescribed by a veterinarian in weight-specific doses for use in conjunction with behavior modification training to treat canine separation anxiety. The drug is proven safe for dogs and puppies 6 months or older.Find more details from the press release.
Comment Preview